Siegbert Kloos - BioNTech Datand Digital
BNTX Stock | USD 86.71 1.38 1.57% |
Executive
Siegbert Kloos is Datand Digital of BioNTech SE
Address | An der Goldgrube 12, Mainz, Germany, 55131 |
Phone | 49 6131 9084 0 |
Web | https://www.biontech.de |
BioNTech Management Efficiency
The company has return on total asset (ROA) of 0.0262 % which means that it generated a profit of $0.0262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0462 %, meaning that it created $0.0462 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.03 in 2024. At this time, BioNTech's Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Debt To Assets are likely to drop 0.01 in 2024.Similar Executives
Showing other executives | EXECUTIVE Age | ||
MD FACP | Crispr Therapeutics AG | 50 | |
Ian Watkins | Novavax | 61 | |
Robert Spiegel | PTC Therapeutics | 64 | |
Solebury Trout | Iovance Biotherapeutics | N/A | |
Karen Tepichin | Ginkgo Bioworks Holdings | N/A | |
Scott Gottesman | AVROBIO | N/A | |
Steven CPA | Ginkgo Bioworks Holdings | N/A | |
Georgette Verdin | AVROBIO | N/A | |
Esq CPA | Ocean Biomedical | 59 | |
John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
Erika Trahan | Novavax | N/A | |
Hubert MD | Krystal Biotech | 55 | |
Clint Wallace | Madrigal Pharmaceuticals | N/A | |
JD Esq | Novavax | 53 | |
Jon Terrett | Crispr Therapeutics AG | N/A | |
Deanna Petersen | AVROBIO | 55 | |
Kim Warren | AVROBIO | N/A | |
PharmD MBA | Madrigal Pharmaceuticals | N/A | |
Brian MBA | Iovance Biotherapeutics | N/A | |
Chris Brinzey | AVROBIO | N/A | |
Phongsakorn Phongsathaphorn | Ginkgo Bioworks Holdings | 32 |
Management Performance
Return On Equity | 0.0462 | ||||
Return On Asset | 0.0262 |
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Katalin Kariko, Senior Therapies | ||
Jens Holstein, CFO Board | ||
Sylke Maas, Vice Strategy | ||
Michael Boehler, MD Communications | ||
Siegbert Kloos, Datand Digital | ||
Sierk Poetting, COO MD | ||
Pr MD, CoFounder Board | ||
Zach Taylor, Senior Strategy | ||
Ozlem MD, Chief CoFounder | ||
Sean Marett, Chief Officer | ||
Oliver Henning, Senior Operations | ||
Oliver Hennig, Senior Operations | ||
Ugur MD, CEO CoFounder | ||
James Ryan, Chief Board | ||
Ryan Richardson, MD Officer | ||
Sebastian MD, Senior Research |
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0462 | ||||
Return On Asset | 0.0262 | ||||
Profit Margin | 0.24 % | ||||
Operating Margin | 0.40 % | ||||
Current Valuation | 4.28 B | ||||
Shares Outstanding | 240.99 M | ||||
Shares Owned By Insiders | 62.84 % | ||||
Shares Owned By Institutions | 18.33 % | ||||
Number Of Shares Shorted | 3.16 M | ||||
Price To Earning | 5.19 X |
BioNTech Investors Sentiment
The influence of BioNTech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioNTech. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioNTech's public news can be used to forecast risks associated with an investment in BioNTech. The trend in average sentiment can be used to explain how an investor holding BioNTech can time the market purely based on public headlines and social activities around BioNTech SE. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioNTech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioNTech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioNTech's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioNTech.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioNTech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioNTech's short interest history, or implied volatility extrapolated from BioNTech options trading.
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving against BioNTech Stock
0.66 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
0.62 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
0.52 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.52 | HCWB | HCW Biologics | PairCorr |
0.49 | FHTX | Foghorn TherapeuticsInc Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.1 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.